Yiying Wang

Cooley advised the underwriters of Duality Biologics (DualityBio), a clinical-stage biotech company focused on the discovery and development of next-generation antibody-drug conjugate therapeutics for patients with cancer and autoimmune diseases, in connection with its HK$1.64 billion global initial public offering (IPO).

Cooley advised the sponsors and underwriters of Jiangsu Zenergy Battery Technologies Group (Zenergy) – a lithium-ion battery manufacturer focusing on the research and development, production and sales of electric vehicle battery products, electrochemical energy storage battery products and aviation battery products – in connection with Zenergy’s HK$1 billion global initial public offering.

Cooley advised the sponsors and underwriters of BrainAurora Medical Technology, a provider of medical diagnostics and digital therapies, in connection with the company’s HK$583 million initial public offering.

Cooley advised the underwriters of Zhejiang Taimei Medical Technology (Taimei), a digital solution provider focused on the pharmaceutical and medical device industry in China, on its HK$335.1 million initial public offering.

Cooley advised Brii Biosciences on its agreements with VBI Vaccines (NASDAQ: VBIV) to ensure expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio’s hepatitis B virus functional cure portfolio. With operations in major biotechnology centers in the US and China, Brii Bio (HKSE: 2137) is a Hong Kong Stock Exchange-listed biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs.